Drug Approval | January 21, 2022
Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
A toll-free helpline to be set up to help doctors and patients
The product is expected to be available in a week’s time
The company will market it under the brand name Molflu
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Expertise in exosomes isolation and characterization will drive innovation in this field
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
Subscribe To Our Newsletter & Stay Updated
